Best biotech stocks to buy in 2022

Biotechnology is a crucial part of our modern lives. This page picks out some of the leading companies in the biotechnology industry and explains what makes them stand out from the competition.
By: Charlie Hancox
Charlie Hancox
Alongside his passion for trading, Charlie has represented Great Britain and won national championships as a water polo player,… read more.
Updated: Oct 14, 2021
Tip: our preferred broker is, eToro: visit & create account

Our financial analysts have picked out the top five biotech companies that are at the top of their field. Additionally, you can find an explanation of the industry as a whole, along with the best place to find these biotech stocks.

What are the top biotech stocks to buy?

The table below contains the five companies our experts have chosen. You can either find up-to-date share price data through the table or scroll down to find out more information about each.

#Stock symbolCompany name
1RGENRegeneron Pharmaceuticals Inc.
2NVAXNovavax, Inc.
3GILDGilead Sciences
4OCGNOcugen Inc.
5NBIXNeurocrine Biosciences, Inc.
List selected by our team of analysts, updated 22 September 2021.

For more information about each company, simply scroll down for more details such as market caps, revenue and product ranges.

1. Regeneron Pharmaceuticals Inc. (NASDAQ: RGEN)

Headquartered in New York and part of both the NASDAQ 100 and S&P 500 indexes, Regeneron Pharmaceuticals is a biotech and pharmaceutical company that was founded in 1988. Regeneron generates around $8 billion of revenue per year and employs over 8,000 staff.

Its top pharmaceutical products include Aflibercept, Arcalyst, Praluent, Dupixent, Kevzara, Libtayo, and Inmazeb, and they are used to treat things like inflammation, blindness, arthritis, cardiovascular disease, cancer and even Ebola. With a market cap of over $50 billion, its sheer scale and the variety of treatments it offers have secured its place on our list. 

Recently, Regeneron was in the news for providing an experimental COVID-19 antibody treatment for President Trump. Its recent share price performance has been solid if a little volatile, though we can foresee growth with the introduction of new treatments.

2. Novavax, Inc. (NASDAQ: NVAX)

Based in Maryland, US, and founded in 1987, Novavax is a pharmaceutical company that creates experimental vaccines for major diseases. It did not have a successful launch until its 2021 NVX-CoV2373 COVID-19 vaccine, and it has now applied for emergency use in the US. It also has a phase 3 clinical trial underway for an influenza vaccine, NanoFlu. 

Given its lack of a successful launch until 2021, its share price has been extremely volatile. However, from 2020 onwards, it has experienced rapid growth and has now has a market cap in excess of $12 billion. This makes it a strong growth stock that has the potential to generate dramatic returns, though its experimental focus comes with increased risks. 

Looking to the future, a major potential catalyst comes in the form of Novavax’s COVID-19 vaccine receiving formal authorisation. Moreover, Novavax claims its vaccine has higher efficacy than some of the major COVID-19 vaccines, though this is largely down to where and how it is tested. If the company can secure approval, it could be en route to profits. 

3. Gilead Sciences (NASDAQ: GILD)

Gilead Sciences is an American company that develops treatments for a variety of life threatening diseases. It’s best known for its treatment for Hepatitis B and C, HIV, and Influenza. Like many of the companies on this list, it was created in the 1980s, and has been public since 1992.

This type of stock often ebbs and flows with the success of its treatments and Gilead is no different. It did well initially out of the pandemic, thanks to a coronavirus treatment called Veklury, that sent its stock soaring above $80 and to its highest price in five years. As other companies developed vaccines, that price began to wane again.

The big thing with any biotech company is its ability to develop new drugs. Successful ones almost guarantee profits for many years but they are difficult to find and so one route is to buy up other companies to grow into new areas. Gilead has done this to get exposure to cancer and cardiovascular medication, so that it has a robust range of treatments for serious illnesses that it can use to turn into long term profits.

4. Ocugen Inc. (NASDAQ: OCGN)

Based in Philadelphia and founded in 2013, Ocugen is a clinical-stage biopharmaceutical company that is focussed on developing treatments for rare eye diseases. 

The main reason it is on our list is because of its potential for dramatic growth. With only around 50 employees and a market cap of just over $2 billion, the company has plenty of headroom, especially considering the company had a dramatically higher valuation a few years ago.

While Ocugen currently produces virtually no revenue, investors are banking on one of its innovative treatments reaching commercialisation, though exactly when this will happen remains to be seen. Ocugen is not a stock for the faint of heart, though, for brave investors with an ambitious eye, it could be a winner. 

5. Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

Neurocrine Biosciences is an American biopharmaceutical company founded in 1992 and based in San Diego, California. The company pioneers treatments for neurological and endocrine-related diseases and disorders.

The company’s main drug, Valbenazine, was approved for use in the US for adults with Tardive Dyskinesia in 2017, and this is the main source of its nearly $800 million yearly revenue. Alongside Valbenazine, Neurocrine is developing treatments at various stages of research for Parkinson’s disease, Tourette syndrome, and congenital adrenal hyperplasia.

The fact that Neurocrine has the inherent value of a profitable treatment combined with numerous potentially lucrative clinical-stage treatments has resulted in the company being on this list. We feel it strikes a nice blend of an $8 billion value stock with plenty of growth potential, as its work with a partner to treat endometriosis and uterine fibroids demonstrates. 

Where to buy the best biotech shares

Generally, the best place to find shares is through a reliable stockbroker with low fees. These are online services that allow you to easily control your entire investment portfolio from a single, user-friendly interface.

Min. Deposit
User Score
Trade/invest in stocks with just $50
Invest for dividends and get payout on stocks on Ex-Dividend day
Over 11 payment methods, including PayPal
Start Trading
eToro is a multi-asset investment platform with more than 2000 assets, including FX, stocks, ETF’s, indices and commodities. eToro users can connect with, learn from, and copy or get copied by other users. Buying stocks on eToro is free and you can invest with as little as $50.
Payment Methods
Bank Transfer, Wire Transfer
Full regulations list:
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Min. Deposit
User Score
0 Commissions and no deposit minimums
Registered with and regulated by SEC and FINRA
Loss of cash protection
Start Trading
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
Payment Methods
Full regulations list:

What is a biotech stock?

A biotech stock is a publicly-traded company that harnesses biological technology. This can include cellular and biomolecular processes with the main aim of creating technologies that enhance quality of life. A simple example of biotechnology that has been used for generations is the fermentation process for certain kinds of cheese. 

Are biotech shares a good investment?

Biotech stocks are high-risk, high-reward investments. Many of them are in the process of developing drugs that could eventually solve major illnesses and address multi-billion dollar markets. 

However, one misstep can have dramatic consequences. For example, if a US-based biotech company receives approval or rejection on one batch of trial data from the U.S. Food and Drug Administration, it can send a stock soaring or plummeting in a matter of minutes. 

The important thing you need to look for in biotech shares is catalyst moments. Before investing, make sure you are aware of the key dates around which a company’s success or failure will be revealed. 

While there can never be true certainty that a biotech stock will be successful, knowing the major milestones can help you anticipate market movements ahead of time. For the latest news on the biotech sector, click on one of our news links below. 

Latest biotech news

Immuron Limited (NASDAQ: IMRN) went up 30% after it announced that it had received $6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan.  This new research agreement with the DoD aims to confirm and test the efficacy of dosing regimens of Travelan…
Berkeley Lights Inc (NASDAQ: BLI) went down 30% after announcing its Chief Executive Officer, Dr. Eric Hobbs will be moving from CEO and a member of the company’s BoD to the Antibody Therapeutics department president. Berkeley Lights is now in search of a new Chief Executive Officer as the…
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was a notable beneficiary of the global pandemic that resulted in a 30% increase in its stock price last year. But BofA Securities warns 2022 will be a very different story. Meacham sees downside to $575 a share In a note on Wednesday, analyst…
Mainz Biomed N.V. (NASDAQ: MYNZ) went up by 80% after it announced that it and Socpra Sciences had executed a Technology Rights Agreement in order to gain access to novel mRNA biomarkers with the goal of integrating them into ColoAlert in the future. ColoAlert is Mainz’s easy-to-use and highly efficacious…
The Nasdaq Biotechnology Index (NBI) has tanked more than 10% in two months, but iCapital’s Anastasia Amoroso says it could double in the coming years. Highlights from Amoroso’s interview on CNBC’s ‘Halftime Report’ After a weak 2021, Amoroso expects NBI to pick up this year. She sees President Biden’s “Build…
AVROBIO Inc (NASDAQ: AVRO) dropped by 30% after announcing it was changing its portfolio priorities to concentrate on other clinical-stage pipeline programs. The company plans to deprioritize the Fabry program because of several reasons, including new clinical findings from the most recent patients given the Phase II FAB-GT drug candidate.

Fact-checking & references

Our editors fact-check all content to ensure compliance with our strict editorial policy. The information in this article is supported by the following reliable sources.

Risk disclaimer

Invezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >

Charlie Hancox
Financial writer
Alongside his passion for trading, Charlie has represented Great Britain and won national championships as a water polo player, and as a budding film director, has… read more.
Jayson Derrick
Lead News Editor
Jayson lives in Montreal with his wife and daughter, loves watching hockey, and is on a lifelong quest to perfect the art of Texas style BBQ. read more.